These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6816163)

  • 61. The staphylococcal surface-glycopolymer wall teichoic acid (WTA) is crucial for complement activation and immunological defense against Staphylococcus aureus infection.
    Kurokawa K; Takahashi K; Lee BL
    Immunobiology; 2016 Oct; 221(10):1091-101. PubMed ID: 27424796
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High rate of Staphylococcus aureus oropharyngeal colonization in children.
    Bádue Pereira MF; Mimica MJ; de Lima Bigelli Carvalho R; Scheffer DK; Berezin EN
    J Infect; 2012 Mar; 64(3):338-40. PubMed ID: 22155659
    [No Abstract]   [Full Text] [Related]  

  • 63. Alanylation of teichoic acids protects Staphylococcus aureus against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model.
    Kristian SA; Lauth X; Nizet V; Goetz F; Neumeister B; Peschel A; Landmann R
    J Infect Dis; 2003 Aug; 188(3):414-23. PubMed ID: 12870123
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serological diagnosis of deep Staphylococcus aureus infections by enzyme-linked immunosorbent assay (ELISA) for staphylococcal hemolysins and teichoic acid.
    Granström M; Julander I; Möllby R
    Scand J Infect Dis Suppl; 1983; 41():132-9. PubMed ID: 6379858
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Complications associated with Staphylococcus aureus bacteremia.
    Libman H; Arbeit RD
    Arch Intern Med; 1984 Mar; 144(3):541-5. PubMed ID: 6703826
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Treatment of severe infections and septicemia caused by S. aureus (author's transl)].
    Coppens L
    Rev Med Brux; 1982 Jun; 3(6):403-8. PubMed ID: 6921830
    [No Abstract]   [Full Text] [Related]  

  • 67. Therapeutic Drug Monitoring Simulator for Antibiotic Dosage for Methicillin-Resistant Staphylococcus aureus Sepsis in a Patient with Primary Immunodeficiency on Peritoneal Dialysis.
    Narazaki H; Terada Y; Kaizu K; Jitsukawa T; Ito Y; Asano T
    J Nippon Med Sch; 2017; 84(4):177-182. PubMed ID: 28978898
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults.
    Weisman LE; Fischer GW; Thackray HM; Johnson KE; Schuman RF; Mandy GT; Stratton BE; Adams KM; Kramer WG; Mond JJ
    Int Immunopharmacol; 2009 May; 9(5):639-44. PubMed ID: 19268719
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Proteinase inhibitors and staphylococcal infections].
    Zolotukhin NA
    Khirurgiia (Mosk); 1972 Sep; 48(9):79-80. PubMed ID: 4661805
    [No Abstract]   [Full Text] [Related]  

  • 71. A comparison of six antistaphylococcal antibiotics.
    Wagner DS; Salstrom SJ; Kungl MJ; File TM; Tan JS
    Curr Surg; 1987; 44(2):114-7. PubMed ID: 3581888
    [No Abstract]   [Full Text] [Related]  

  • 72. Treatment of dialysis catheter-related Staphylococcus aureus bacteremia with an antibiotic lock: a quality improvement report.
    Maya ID; Carlton D; Estrada E; Allon M
    Am J Kidney Dis; 2007 Aug; 50(2):289-95. PubMed ID: 17660030
    [TBL] [Abstract][Full Text] [Related]  

  • 73. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.
    Ploy MC; Grélaud C; Martin C; de Lumley L; Denis F
    Lancet; 1998 Apr; 351(9110):1212. PubMed ID: 9643727
    [No Abstract]   [Full Text] [Related]  

  • 74. IgM and IgG antibody response to teichoic acid in infections due to Staphylococcus aureus.
    Wheat J; Kohler RB; White A; Garten M; Wilkinson BJ
    J Infect Dis; 1983 Jun; 147(6):1101. PubMed ID: 6854065
    [No Abstract]   [Full Text] [Related]  

  • 75. Prognostic value of teichoic acid antibodies in Staphylococcus aureus bacteremia: a reassessment.
    Tenenbaum MJ; Archer GL
    South Med J; 1980 Feb; 73(2):140-3, 149. PubMed ID: 6766569
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Significance of the determination of teichoic acid antibodies in the diagnosis of Staphylococcus aureus bacteremia].
    Herzog C; Just V; Berger R; Just M
    Schweiz Med Wochenschr; 1986 Mar; 116(11):331-5. PubMed ID: 3961450
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Staphylococcus aureus: cellular biology and clinical application.
    Kaplan MH; Tenenbaum MJ
    Am J Med; 1982 Feb; 72(2):248-58. PubMed ID: 7058835
    [No Abstract]   [Full Text] [Related]  

  • 78. Staphylococcus aureus. The persistent pathogen (second of two parts).
    Sheagren JN
    N Engl J Med; 1984 May; 310(22):1437-42. PubMed ID: 6371536
    [No Abstract]   [Full Text] [Related]  

  • 79. Treating Staphylococcus aureus bacteremia.
    Fernandez Guerrero ML; Gómez Garcés JL; Arnal P
    Arch Intern Med; 1982 Dec; 142(13):2346-7. PubMed ID: 6816163
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.